Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, Göskel T, Cortot AB, Girard N, Wesseler C, Bischoff H, Nadal E, Park K, Lu S, Taus A, Cobo M, Estrem ST, Wijayawardana SR, Turner K, Oakley GJ 3rd, Hurt KC, Chiang AY, Hossain AM, John WJ, Paz-Ares L. Goldman JW, et al. Among authors: taus a. Front Oncol. 2020 Oct 26;10:578756. doi: 10.3389/fonc.2020.578756. eCollection 2020. Front Oncol. 2020. PMID: 33194700 Free PMC article.
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-Noguera J, Felip E, Nadal E, Malfettone A, Sampayo M, Riva F, Nagy RJ, Lanman RB, Faull I, Dix D, Karachaliou N, Rosell R. Palmero R, et al. Among authors: taus a. JCO Precis Oncol. 2021 Nov;5:93-102. doi: 10.1200/PO.20.00241. JCO Precis Oncol. 2021. PMID: 34994593
[No title available]
[No authors listed] [No authors listed] PMID: 37784847
Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer.
Clavé S, Jackson JB, Salido M, Kames J, Gerding KMR, Verner EL, Kong EF, Weingartner E, Gibert J, Hardy-Werbin M, Rocha P, Riera X, Torres E, Hernandez J, Cerqueira G, Nichol D, Simmons J, Taus Á, Pijuan L, Bellosillo B, Arriola E. Clavé S, et al. Among authors: taus a. Front Oncol. 2023 Oct 20;13:1225646. doi: 10.3389/fonc.2023.1225646. eCollection 2023. Front Oncol. 2023. PMID: 37927472 Free PMC article.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: taus a. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.
Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, Bernet L, Majem M, Bosch-Barrera J, Porta R, Alonso N, Palmero R, Taus A, Albanell J, Espinet B, Salido M, Arriola E. Vidal J, et al. Among authors: taus a. J Thorac Oncol. 2014 Dec;9(12):1816-20. doi: 10.1097/JTO.0000000000000361. J Thorac Oncol. 2014. PMID: 25393795 Free article.
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Gibert J, Clavé S, Hardy-Werbin M, Taus Á, Rocha P, Longarón R, Piquer G, Chaib I, Carcereny E, Morán T, Salido M, Dalmases A, Bellosillo B, Arriola E. Gibert J, et al. Among authors: taus a. Lung Cancer. 2020 Feb;140:42-45. doi: 10.1016/j.lungcan.2019.12.003. Epub 2019 Dec 5. Lung Cancer. 2020. PMID: 31862576
Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.
Taus Á, Camacho L, Rocha P, Hernández A, Longarón R, Clavé S, Fernández-Ibarrondo L, Salido M, Hardy-Werbin M, Fernández-Rodríguez C, Albanell J, Bellosillo B, Arriola E. Taus Á, et al. Arch Bronconeumol (Engl Ed). 2021 May;57(5):323-329. doi: 10.1016/j.arbres.2020.01.023. Epub 2020 Apr 3. Arch Bronconeumol (Engl Ed). 2021. PMID: 32253118 English, Spanish.
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage.
Conde-Estévez D, Monge-Escartín I, Ríos-Hoyo A, Monzonis X, Echeverría-Esnal D, Moliner L, Duran-Jordà X, Taus Á, Arriola E. Conde-Estévez D, et al. Among authors: taus a. J Chemother. 2021 Feb;33(1):32-39. doi: 10.1080/1120009X.2020.1849488. Epub 2020 Dec 3. J Chemother. 2021. PMID: 33267748
48 results